World Congress on Huntington's Disease to meet in Toronto, August 16-19, 2003

July 26, 2003

(Toronto, Ontario, Canada) -- Huntington's disease (HD) researchers, clinicians, and members of the HD community from around the world will convene August 16-19 in Toronto, Ontario, Canada for the World Congress on Huntington's Disease. A scientific program will feature presentations on the genetics and mechanisms of HD, as well as recent discoveries and experimental treatments. Research clinicians working with families affected by HD will present the latest findings from clinical trials. The Congress will also include sessions on social, historical, and ethical perspectives of HD, as well as implications for public policy and education.

HD is an inherited, progressive disease of the nervous system that affects about 1 in 10,000 people worldwide. In Canada and the United States, about 30,000 individuals are ill from HD, and another 150,000 risk developing this disorder. The degeneration of brain cells, called neurons, in certain areas of the brain leads to psychiatric, intellectual, and movement problems. Because the disease is inherited in an autosomal dominant fashion, each child of a person with HD has a 50% risk of also developing the disease. There is currently no proven therapy or cure that can slow or prevent the disease.

Research in HD has increased dramatically in the past decade, since the 1993 identification of the gene responsible for the disease. Investigators from 20 countries, representing the United States, Canada, Australia, Europe, Brazil, Cuba, Iran, Turkey, Israel and Asia will all be presenting recent research findings at the Congress.

The World Congress on Huntington's Disease (HD) is a newly-structured international forum to present and discuss research and public policy topics, supported by and under the auspices of the World Federation of Neurology Research Group on Huntington's Disease, the International Huntington Association, the Huntington Society of Canada, the Hereditary Disease Foundation (HDF), the Huntington's Disease Society of America (HDSA), and the Huntington Study Group (HSG). The Congress will be hosted by the Huntington Society of Canada, a national network of volunteers and professionals working together to find new treatments and, ultimately, a cure for Huntington disease; and to improve the quality of life of individuals with Huntington disease and their families across Canada.
Qualified media are invited to attend and registration is complimentary. For further information, see, or call Leslie Briner at 585-275-1068, or Isla Horvath at 519-749-7063.

World Congress on Huntington's Disease

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to